Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA
Accessnewswire·2025-10-28 14:20
Contact Us Back to the Newsroom Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA Tuesday, 28 October 2025 10:20 AM Topic:Â Company Update Exousia Pro is in a unique position, as only 11% of ODAs are awarded at the preclinical stage. ORLANDO, FLORIDA / ACCESS Newswire / October 28, 2025 / Exousia Pro, Inc. (formerly Marijuana, Inc.) (OTCPINK:MAJI), a clinical-stage biotech company using exosomes in the treatment of cancer and other maladies, is pleased to announce ...